Revolution Medicines Inc.
Revolution Medicines Announces 2025 Financial Results and Corporate Progress
Summary
Revolution Medicines, Inc. reported its financial results for the year ended December 31, 2025, highlighting increased R&D and G&A expenses, leading to a net loss of $1.1 billion. Despite the higher expenses, the company's cash position remained robust at $2.0 billion, bolstered by a $250 million upfront payment from Royalty Pharma. The company also provided an update on its clinical pipeline, with several Phase 3 trials underway and promising preliminary results for its RAS(ON) inhibitors. Revolution Medicines anticipates key data readouts in the first half of 2026, particularly for its pancreatic cancer drug, daraxonrasib.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement